Introduction
The oncology therapeutic landscape has evolved substantially, with innovations affecting not only treatments but also care organization. In this regard, it has been reshaped by the introduction of subcutaneous (SC) formulations of several monoclonal antibodies (mAbs) previously available only as intravenous (IV) infusions. These formulations represent a relevant route-of-administration innovation within the Italian regulatory framework, consistent with the 2025 AIFA criteria for therapeutic innovativeness, which consider not only efficacy and safety but also route of administration, impact on quality of life, and organizational implications for healthcare delivery (1). Beyond their established clinical value, SC formulations provide tangible advantages related to faster and less invasive administration, reduced hospital time for patients and caregivers, improved quality of life, and lower direct and indirect healthcare costs (Reference Pivot, Gligorov and Müller2;Reference Davies, Merli and Mihaljevic3). Importantly, by shortening chair occupancy, SC administration can release capacity within day-hospital services, allowing more patients to be treated with the same infrastructure (Reference Bittner, Richter and Schmidt4). These attributes are particularly relevant in high-volume oncology centers, where optimization of healthcare resources and efficiency is crucial to sustain both conventional and experimental therapeutic pathways.
The IV-to-SC transition is particularly relevant for high-dose monoclonal antibodies that were originally developed as IV formulations when enabling technologies for SC delivery of large protein doses, such as high-concentration formulations and recombinant human hyaluronidase, were not yet available or routinely implemented. In addition, IV administration allowed gradual infusion regimens to mitigate infusion-related reactions observed with some early monoclonal antibodies. Conversely, lower-dose monoclonal antibodies or agents with more favorable administration profiles may be developed directly with an SC regimen.
Clinical evidence for SC formulations
Clinical non-inferiority of SC formulations has been demonstrated across several oncology monoclonal antibodies, including trastuzumab, rituximab, daratumumab, and atezolizumab (Reference Jackisch, Stroyakovskiy and Pivot5;Reference Davies, Merli and Mihaljević6). More recently, the FeDeriCa study validated a ready-to-use fixed-dose SC co-formulation of pertuzumab and trastuzumab, administered with recombinant human hyaluronidase as an enzymatic dispersion enhancer through a single SC injection, confirming non-inferior pharmacokinetics and comparable safety profiles (Reference DuMond, Patel, Gross, Fung and Weber7;Reference Aguiar-Ibáñez, Fotheringham, Mittal, Sillah and Pathak8). The IMscin001 phase III trial extended this evidence to immunotherapy, demonstrating non-inferior exposure, efficacy, and immunogenicity of SC atezolizumab compared with IV administration in advanced non-small cell lung cancer (NSCLC) (Reference Aguiar-Ibáñez, Fotheringham, Mittal, Sillah and Pathak8). Overall, these findings support SC formulations as clinically valid alternatives to IV administration. Since clinical non-inferiority and safety have already been extensively demonstrated, the major unresolved issue for healthcare providers concerns their organizational and economic implementation in routine practice. In particular, the potential impact of IV-to-SC transitions on pharmacy workload, nursing time, chair occupancy, treatment capacity, and resource sustainability requires structured evaluation within real-world hospital settings.
Patient and healthcare professional perspectives
From the patient perspective, SC administration reduces treatment time, limits disruption to daily life, and lowers indirect costs. Patient preference studies consistently report a strong preference for SC delivery due to greater convenience and comfort, while time-and-motion analyses in oncology centers have documented substantial time savings per cycle, with both hospital and societal benefits. From the healthcare professional perspective, SC administration streamlines preparation and delivery processes, enabling more efficient use of pharmacy and nursing resources and increased patient throughput (Reference Pivot, Gligorov and Müller2;Reference Aguiar-Ibáñez, Fotheringham, Mittal, Sillah and Pathak8–Reference Busschaert, Werbrouck, De Ridder and Putman11). Despite these advantages, adoption of SC formulations in routine practice remains heterogeneous across settings (Reference Wardley, Canon and Elsten12). This variability highlights the importance of health technology assessment (HTA) approaches capable of balancing clinical value with economic and organizational implications, particularly in capacity-constrained oncology day-hospital settings where SC formulations may support service reorganization and capacity release.
Policy context and evolving care models
In Italy, the value of new formulations is framed by the Italian Medicines Agency (AIFA) criteria for therapeutic innovativeness, which extend beyond efficacy and safety to also include the production technology of the active substance, its mechanism of action, route of administration, impact on patient quality of life, and the organizational implications for healthcare delivery (1). SC formulations thus fit into a multidimensional framework of therapeutic value, encompassing clinical, patient-centered, and organizational dimensions of innovation (Reference Keel, Savage, Rafiq and Mazzocato10). However, while these criteria provide a conceptual basis, their operational translation into systematic comparative frameworks is still lacking. Furthermore, the simplified administration associated with SC formulations may be compatible with evolving decentralized care pathways and organizational models aimed at reducing hospital-based treatment burden (13).
Study rationale
Taken together, current evidence highlights a critical gap. Although SC formulations of mAbs are clinically validated and increasingly integrated into healthcare policy and organizational innovation pathways, structured approaches to support their implementation remain limited. This study contributes to the development of a transferable hospital-based multidisciplinary framework by focusing on the economic, organizational, operational, and resource-allocation implications of partial or complete IV-to-SC transitions across different care settings (hospital-based, outpatient, or community-based care settings) (13). These evaluations should preferably be conducted at an early stage, as soon as the reimbursed formulation becomes available, to ensure timely access, support care pathway redesign, and maximize patient benefit.
This analysis captures a pre–price-alignment phase, preceding national and regional renegotiations between SC and IV formulations. The economic evaluation of IV-to-SC transitions is further influenced by biosimilar market entry for IV formulations, which may reduce IV acquisition costs and widen or modify the acquisition cost differential between IV and SC alternatives. This makes local price conditions and timing of assessment critical determinants of budget impact.
The present article addresses this need by developing and applying a comprehensive, multidisciplinary, and transferable framework for the economic and organizational evaluation of IV-to-SC transitions in oncology. Drawing upon pivotal clinical trials, real-world evidence, and healthcare policy frameworks, the proposed model combines budget impact analysis, organizational assessment, resource-utilization analysis, and scenario-based simulations to support decision making regarding IV-to-SC transitions.
Methods
Study design
This study was designed according to a hospital-based health technology assessment (HB-HTA) approach, integrating clinical, economic, organizational, and operational dimensions relevant to institutional decision making regarding IV-to-SC transitions in oncology (Reference Di Bidino, Lipska and Kukla9). Specifically, the assessment used local institutional data, real-world workflows, pharmacy and nursing resource estimates, and scenario-based analyses to inform hospital-level adoption and implementation decisions. The analysis was conducted in a high-volume oncology center and included two anonymized case studies, antibody X and antibody Y, to maintain focus on the methodological framework rather than product-specific conclusions.
Eligibility criteria
For both drugs, eligibility was defined in accordance with the reimbursed therapeutic indications established by AIFA and, when applicable, the prescribing criteria specified in the AIFA monitoring registries. Patients treated during 2024 were identified from institutional registries and included according to the approved therapeutic setting. The number of eligible patients was identified through institutional oncology pharmacy and prescribing registries, which routinely record treatment indication, setting, regimen, administration dates, and number of cycles. These registries are used for institutional monitoring and represent the official source of real-world treatment activity within the center. Cohorts were stratified by treatment intent (e.g., neoadjuvant, adjuvant, first-line metastatic, and subsequent metastatic lines) or by treatment regimen (e.g., monotherapy vs. combination therapy), as appropriate.
Variables and cost components
The comparative analysis focused on direct cost differentials between IV and SC formulations, incorporating:
-
• drug acquisition costs;
-
• pharmacy preparation and administration costs, with production costs estimated using the Time-Driven Activity-Based Costing (TDABC) methodology (Reference Keel, Savage, Rafiq and Mazzocato10). This approach, widely validated in healthcare settings, was applied in accordance with Veneto Regional Government Resolution (DGR) n. 833/2025, which updated the technical and organizational standards for centralized antineoplastic drug preparation units (UFA) and defined a regional standard tariff for compounding activities according to preparation complexity (Reference Munzone, Fabi and Buono14–Reference O’Shaughnessy, Sousa and Cruz16). TDABC considers not only production volumes but also additional parameters that better capture the organizational complexities of hospital pharmacy processes. Compounding time is used as the primary cost driver, allowing each preparation to be classified into predefined complexity levels (short <9 minutes, medium 10–20 minutes, and long >20 minutes) and a unit cost to be assigned to each category.
-
• consumable costs were assessed qualitatively, as itemized data were not consistently available. They included infusion materials, syringes, administration sets, personal protective equipment, and venous access-related materials, but were not included as separate quantitative cost drivers;
-
• nursing administration time;
-
• savings from avoided central venous access device placement (e.g., PICC and port);
-
• analysis and organizational impact.
For each therapeutic setting (including neoadjuvant, adjuvant, and metastatic settings), the model evaluated:
-
• overall budget impact of the IV → SC switch.
-
• organizational and logistical impact, including day-hospital operations across two institutional sites, chair utilization and turnover, and cumulative chair time released (in minutes) for reallocation to other oncology treatments. The total time saved was then divided by the average administration time of a generic oncological therapy (124 min) (Reference Munzone, Fabi and Buono14).
-
• relative annual increase (percent) in patient throughput achievable due to efficiency gains.
Scenario analyses
Different scenario structures were used for antibody X and antibody Y, because their clinical use differed in the institutional setting. Antibody X was used across multiple therapeutic settings, including neoadjuvant, adjuvant, and metastatic treatment, requiring setting-specific scenarios. Antibody Y was evaluated in monotherapy, allowing scenarios based on different proportions of eligible patients switched to SC administration. For antibody Y, three scenarios were modeled:
-
• the current practice scenario assumed administration exclusively via the IV formulation for all eligible patients.
-
• two mixed scenarios were developed to simulate partial adoption of the SC formulation: in Scenario A, 36 percent of patients receiving antibody Y in monotherapy were switched to SC, while in Scenario B, the proportion was increased to 50 percent.
-
• a full switch scenario (Scenario C) assumed that 100 percent of patients receiving antibody Y in monotherapy were treated with the SC formulation.
For antibody Y, the average production cost of each preparation was estimated using the TDABC methodology (Reference Keel, Savage, Rafiq and Mazzocato10). Both IV and SC antibody Y preparations fall into the short-preparation category and, therefore, no economic/time savings were found in terms of pharmacy activities. Since the cost per milligram of antibody Y is the same for both available dosages (1,200 mg and 840 mg), the 1,200 mg dose was considered for simplicity, corresponding to one vial per administration, as in the case of the SC formulation. Dosing was based on a q3w schedule of 1,200 mg per administration, in line with the therapeutic protocol. The mean number of treatment cycles was 7.7, calculated as the weighted average from institutional registry data for patients treated with antibody Y monotherapy.
For antibody X, a wide-ranging spectrum of scenarios was explored, reflecting the diverse clinical settings considered:
-
• The current practice scenario reflected administration exclusively through the IV formulation in all treatment settings.
-
• Several partial switch scenarios simulated the adoption of the SC formulation in specific subgroups of patients, stratified by therapeutic setting: neoadjuvant, adjuvant, first-line metastatic, and subsequent metastatic lines beyond the first. In each case, the remaining patients were assumed to continue receiving IV therapy.
-
• A full switch scenario was also included, assuming that 100 percent of patients across all settings transitioned to the SC formulation.
For antibody X, dosing was based on the average body weight of the IOV population (65.2 kg). The purchase cost of the biosimilar of antibody X was considered, and the maintenance therapy regimen was applied. The average production cost of each preparation was estimated using the TDABC methodology (Reference Kaplan and Porter17), recently adopted at the regional level, which assigns costs according to preparation complexity. Specifically, IV compounding of antibody X corresponds to a medium-complexity preparation, whereas SC compounding is classified as a short-complexity preparation. The mean number of treatment cycles was estimated at eight, calculated as the weighted average across all treatment settings: four cycles in the neoadjuvant setting (according to the technical product information), eleven cycles in the adjuvant setting (2024 institutional data), and seven cycles in the metastatic setting (2024 institutional data).
A summary of the scenarios considered and the variables included in the comparative model for both antibody Y and antibody X is reported in Table 1.
Scenario analyses and variables considered for IV-to-SC transition

Table 1. Long description
The table compares the scenario analyses for two anonymized drugs, Y and X. For drug Y, scenarios include current practice with 100 percent intravenous administration, 36 percent subcutaneous adoption in monotherapy, 50 percent subcutaneous adoption in monotherapy, and 100 percent subcutaneous adoption in monotherapy. For drug X, scenarios include current practice with 100 percent intravenous administration, partial subcutaneous switch scenarios by treatment setting (neoadjuvant, adjuvant, first-line metastatic, and at least second-line metastatic), and a full 100 percent subcutaneous switch across all settings. Variables included for both drugs are drug acquisition costs, pharmacy validation and compounding costs estimated using time-driven activity-based costing, qualitative assessment of consumables, nursing administration activities, savings from avoiding PICC or port insertion, day-hospital logistics across the Padova and Castelfranco Veneto sites, chair management and turnover, and the number of therapies or chairs released under each scenario.
Implementation framework and transferability
The model compared current IV administration with partial or complete SC adoption scenarios. For each scenario, the framework integrated eligible patient numbers, treatment setting, average treatment cycles, drug acquisition costs, pharmacy preparation complexity, nursing administration time, chair occupancy, and avoided venous access device placement, where applicable. Outputs included incremental budget impact, chair time released, number of additional treatments potentially deliverable, and relative increase in annual treatment capacity.
To facilitate transferability of the proposed framework across different healthcare settings, the model was structured around a set of core data elements and operational assumptions.
The minimum data requirements included:
-
• number of eligible patients by therapeutic setting,
-
• treatment schedules and average number of cycles;
-
• local acquisition costs for IV and SC formulations;
-
• pharmacy preparation complexity and compounding times;
-
• nursing administration times;
-
• chair occupancy duration;
-
• organizational characteristics of the oncology day-hospital setting;
-
• costs associated with venous access devices, where applicable.
When direct time-motion measurements were unavailable, assumptions were based on institutional workflow analyses, published literature, technical product information, and regional organizational standards. The framework was intentionally designed to remain adaptable to different hospital settings, including centers with different patient volumes, pharmacy organization models, and treatment capacities.
Additional refinements could be incorporated in future applications, including direct patient costs, indirect societal costs, patient-reported outcomes, environmental sustainability indicators, and prospective time-motion analyses.
Results
Fixed-dose combination of X for SC injections
Based on the 2024 institutional registries of IOV, a total of 198 patients received IV antibody X. Patients were distributed across treatment settings as follows: forty in the neoadjuvant setting (20 percent), thirty in the adjuvant setting (15 percent), and ninety-eight in the first-line metastatic setting (50 percent), with an additional subset treated in subsequent metastatic lines, for a cumulative 128 patients (65 percent of the metastatic population).
Scenario A: adjuvant setting (≈15 percent, 30/198 patients)
Switching patients in the adjuvant setting to the SC formulation released 13,200 minutes per year of chair time, corresponding to 106 additional oncology treatments and a 7 percent relative annual increase in treatment capacity, with an incremental budget impact of €16,925.70 per year (Figure 1).
Overall budget impact of direct costs between scenario 1 (100 percent SC in the adjuvant setting) and scenario 2 (IV), showing cost increments and savings across components.

Figure 1. Long description
Figure 1 is a waterfall chart comparing scenario 1, 100 percent switch to subcutaneous formulation in the adjuvant setting, with scenario 2, intravenous formulation. The y-axis is overall budget impact in euros, ranging from €0 to €30,000. The chart shows a direct drug cost increment of €29,370.00. This is partly offset by savings of €8,349.00 in nursing activity costs and €4,095.30 in pharmacy activity costs. The resulting subtotal, or overall annual budget impact of direct costs, is €16,925.70.
Scenario B: neoadjuvant setting (≈20 percent, 40/198 patients)
Adopting the SC formulation in neoadjuvant patients resulted in 8,800 minutes per year of chair time savings, enabling eighty-one additional treatments and a 4 percent increase in annual treatment capacity at an incremental budget impact of €3,896.40 per year (Figure 2).
Overall budget impact of direct costs between scenario 1 (100 percent SC in the neoadjuvant setting) and scenario 2 (IV), showing drug cost increases and savings from nursing, pharmacy, and PICC/port avoidance (€3,896.40/year). In calculating the cost savings related to the avoidance of PICC or port placement, a number of 20 out of 40 patients was considered. This is because, according to therapeutic protocols in the neoadjuvant setting, some patients also receive chemotherapy, which implies the need for PICC or port insertion despite administration of the subcutaneous formulation of antibody X.

Figure 2. Long description
Figure 2 is a waterfall chart comparing scenario 1, 100 percent switch to subcutaneous formulation in the neoadjuvant setting, with scenario 2, intravenous formulation. The y-axis is overall budget impact in euros, ranging from €0 to €15,000. The chart shows a direct drug cost increment of €14,240.00. This is partly offset by savings of €4,048.00 in nursing activity costs, €4,310.00 from avoided PICC or port placement, and €1,985.60 in pharmacy activity costs. The resulting subtotal, or overall annual budget impact of direct costs, is €3,896.40. Savings for avoided PICC or port placement were calculated for 20 of 40 patients, because some neoadjuvant patients also receive chemotherapy requiring central venous access despite SC antibody X.
Scenario C: first-line metastatic setting (≈50 percent, 98/198 patients)
Transitioning half of the first-line metastatic population to SC administration freed 37,730 minutes per year, corresponding to 304 additional oncology treatments and a 19 percent relative increase in annual treatment capacity with an incremental budget impact of €35,184.94 per year (Figure 3).
Overall budget impact of direct costs between scenario 1 (100 percent switch to the subcutaneous formulation in the metastatic setting) and scenario 2 (intravenous formulation), showing drug cost increases and savings from nursing and pharmacy activities (€35,184.94/year).

Figure 3. Long description
Figure 3 is a waterfall chart comparing scenario 1, 100 percent switch to subcutaneous formulation in the first-line metastatic setting, with scenario 2, intravenous formulation. The y-axis is overall budget impact in euros, ranging from €0 to €80,000. The chart shows a direct drug cost increment of €61,054.00. This is partly offset by savings of €17,355.80 in nursing activity costs and €8,513.26 in pharmacy activity costs. The resulting subtotal, or overall annual budget impact of direct costs, is €35,184.94.
Scenario D: – all metastatic patients (≈65 percent, 128/198 patients)
Extending the use of the SC formulation to all metastatic patients, including both first-line and subsequent lines, released 49,280 minutes per year, equivalent to 397 additional oncology treatments and a 25 percent increase in annual treatment capacity, with an incremental budget impact of €45,955.84 per year (Figure 4).
Budget impact of direct costs between scenario 1 (100 percent SC in metastatic ≥1 L) and scenario 2 (IV), showing drug cost increases and savings, with a net impact of €45,955.84/year.

Figure 4. Long description
Figure 4 is a waterfall chart comparing scenario 1, 100 percent switch to subcutaneous formulation in the metastatic setting at first line or later, with scenario 2, intravenous formulation. The y-axis is overall budget impact in euros, ranging from €0 to €80,000. The chart shows a direct drug cost increment of €79,744.00. This is partly offset by savings of €22,668.80 in nursing activity costs and €11,119.36 in pharmacy activity costs. The resulting subtotal, or overall annual budget impact of direct costs, is €45,955.84.
Full switch scenario: – all patients (100 percent, 198/198 patients)
A complete transition to the SC formulation across all treatment settings resulted in a 36 percent relative annual increase in the number of patients treated with antibody X, with an incremental drug expenditure of €123,354 per year and an overall budget impact of €66,777.94 per year.
SC formulation of antibody Y
Based on the 2024 IOV institutional registries, a total of 140 patients received IV antibody Y in monotherapy.
Scenario A: 36 percent SC adoption (50/140 patients)
Transitioning 36 percent of patients to SC administration released 8,855 minutes per year of chair time, corresponding to seventy-one additional oncology treatments and a 7 percent relative increase in treatment capacity, with an overall budget impact of €2,382.38 per year (Supplementary Figure S1).
Scenario B: 50 percent SC adoption (70/140 patients)
Switching half of the monotherapy population to SC freed 12,397 minutes/year, enabling 100 additional treatments and a 9 percent relative capacity increase, with an overall budget impact of €3,335.33/year (Supplementary Figure S2).
Scenario C: Full switch (140/140 patients)
A complete transition to SC administration across all patients treated with antibody Y in monotherapy released 24,794 minutes/year, corresponding to 200 additional treatments and a 19 percent relative increase in treatment capacity. This was associated with an incremental drug expenditure of €42,473.20/year, resulting in an overall budget impact of €6,670.55/year (Supplementary Figure S3).
Discussion
The comparative framework developed in this study enabled a prospective evaluation of the organizational and economic consequences of IV-to-SC transitions in oncology, providing structured support for evidence-based decision making, particularly during the interim phase preceding therapeutic formulary inclusion. Within this context, the model facilitated the definition of initially restrictive adoption criteria, narrower than those approved for reimbursement by AIFA or specified in the eligibility forms of the AIFA monitoring registries. Specifically, the SC formulation of antibody X was prioritized for patients with poor or absent venous access across treatment settings, in the neoadjuvant and adjuvant settings (restricted to monotherapy maintenance), while SC antibody Y was considered for patients with poor venous access or those treated in monotherapy to allow the earliest access post-reimbursement.
Application of the model to real-world data from the regional reference oncology institute, integrated with published evidence and economic simulation, demonstrated that even partial substitution yielded measurable organizational benefits. Across both case studies, partial and complete IV-to-SC substitution generated measurable capacity gains with limited incremental budget impact, although the magnitude varied by antibody, treatment setting, and eligible population.
Although our analysis did not directly assess efficacy, safety, or quality-of-life outcomes, the organizational and economic findings are supported by extensive literature. Pivotal trials, such as HannaH, FeDeriCa, SABRINA, and COLUMBA, have already demonstrated the non-inferiority of SC versus IV monoclonal antibodies across multiple tumor types (Reference Jackisch, Stroyakovskiy and Pivot5–Reference DuMond, Patel, Gross, Fung and Weber7;Reference Tan, Im and Mattar18). Furthermore, patient preference studies, including PrefHer and PHranceSCa, consistently reported that more than 80 percent of patients favored SC administration for its convenience and shorter treatment time (Reference Pivot, Gligorov and Müller2;Reference De Cock, Kritikou and Sandoval19). Our results are also consistent with time-and-motion analysis documenting efficiency gains (Reference De Cock, Kritikou and Sandoval19), such as the PHASTER study (Reference Munzone, Fabi and Buono14), which confirmed the significant organizational and economic advantages of SC formulations. These findings are also consistent with recent systematic reviews highlighting the multidimensional implications of IV versus SC oncology therapies from clinical, economic, organizational, and patient perspectives (Reference George, Bourlon and Overman20).
Importantly, the model incorporated all productive factors characteristic of a high-complexity compounding center operating across two institutional sites, thereby capturing both clinical workflows and the economic-organizational contributions of hospital pharmacy.
Organizationally, the IV-to-SC transition affects multiple workflow components, including pharmacy preparation activities, nursing administration time, chair occupancy, venous access management, patient scheduling, and treatment flow within the oncology day-hospital. In the present framework, these organizational implications were operationalized through measures of released chair time, additional treatments potentially deliverable, and changes in resource utilization, while personnel costs were conservatively assumed to remain fixed.
An important strength of the proposed framework lies in its potential transferability across different oncology settings. Because the model is based on routinely available institutional and operational variables, it may be adapted to hospitals with different organizational structures, treatment capacities, and monoclonal antibody pathways. Nevertheless, implementation requires context-specific calibration of workflow assumptions, local acquisition costs, and resource utilization patterns. Prospective validation in additional institutional settings would further strengthen the generalizability of the framework.
First, the organizational benefits associated with shorter chair occupancy and accelerated workflows translate into tangible value only where latent demand exists, such as waiting lists, capacity constraints, or growth potential. In centers without sufficient demand to accommodate additional patients, released chair time may not translate into higher throughput or revenue; under these conditions, switching to SC may result in a net economic loss if higher acquisition costs are not offset by variable-cost reductions. In the current therapeutic context, however, acquisition cost differences between SC and IV formulations are progressively decreasing due to biosimilar competition and price renegotiation processes. Consequently, strict break-even thresholds based exclusively on additional treatment throughput may become less relevant over time, while organizational efficiency, workflow optimization, and resource reallocation are likely to represent increasingly important determinants of value. Future applications of the framework could nevertheless incorporate threshold analyses in settings where substantial acquisition cost differentials between IV and SC formulations remain present. In the present model, released chair time was assumed to be potentially reallocable to additional oncology treatments, reflecting the operational reality of high-volume oncology centers. However, this assumption may not apply uniformly across all settings. In centers with lower demand pressure, time savings may instead translate into reduced workload burden, greater scheduling flexibility, shorter waiting times, or reallocation of healthcare professional time toward other clinical activities rather than increased treatment throughput. Second, even when time-and-motion savings in nursing and pharmacy activities – and avoidance of central venous access – are realized, a residual acquisition cost gap between SC and IV may remain the primary driver of budget impact. This pattern suggests that the historical SC–IV price differential was larger than warranted by identifiable productive factors. From this perspective, comparative economic analyses such as the present one are valuable in highlighting potential market distortions and informing subsequent pricing adjustments. Indeed, the subsequent price alignment observed at national and regional levels appears consistent with this interpretation.
A limitation, however, is that the overall budget balance from IV-to-SC substitution cannot be directly translated into pharmaceutical expenditure ceilings managed in silos. In some healthcare systems, including the Italian context, this silo-based financial organization may hinder the optimization of patient care pathways, leading to increased pharmaceutical expenditure even when efficiency gains are achieved elsewhere. Nevertheless, from a broader health-system perspective, SC formulations contribute to therapeutic appropriateness, rational resource allocation, and overall system efficiency, ultimately improving the patient experience (1;Reference Kaplan and Porter17;Reference George, Bourlon and Overman20).
The recent experience with price renegotiation processes further deserves consideration. In several cases, acquisition cost convergence between SC fixed-dose combinations and their IV counterparts may reflect the combined effect of biosimilar market entry, competitive pricing pressure on originator IV formulations, confidential discounts, regional or national renegotiations, and procurement strategies. These dynamics are highly context-dependent and may substantially alter the budget impact of IV-to-SC transitions over time. While such developments may reduce the immediate applicability of earlier budget impact estimates, they reinforce the need for dynamic reassessment frameworks capable of incorporating updated acquisition costs, biosimilar competition, and local procurement conditions (Reference DuMond, Patel, Gross, Fung and Weber7;Reference Wardley, Canon and Elsten12;Reference Munzone, Fabi and Buono14;Reference Homšek, Spasić and Nikolić21).
Overall, these findings demonstrate that IV-to-SC transition modeling represents a dynamic and adaptable methodology for formulary decision making. Even when acquisition prices converge, such frameworks remain essential to capture the full multidimensional value of therapeutic innovation – balancing clinical benefit, organizational efficiency, and economic sustainability in oncology care.
Conclusions
This study developed and applied a multidisciplinary and transferable model to compare IV and SC formulations of monoclonal antibodies in oncology from an economic–organizational perspective, with a focus on system efficiency. By integrating published evidence with local real-world organizational data and economic simulations, the framework provides a structured methodology for evaluating IV-to-SC transitions in clinical practice.
The findings indicate that SC adoption – while maintaining the clinical equivalence demonstrated in pivotal trials – can deliver substantial organizational and economic benefits, including increased treatment capacity, improved workflow efficiency, and enhanced patient-centered care. These outcomes, however, are context-dependent, reflecting the activity volumes, case mix, and operational complexity of high-specialty oncology centers. Accordingly, while the model is designed to be replicable and adaptable, quantitative estimates should not be extrapolated to institutions with markedly different structural or demand characteristics (the comparative organizational and economic evaluation template has been made available as Supplementary Model S1). Broader application at regional or national levels requires formal evaluation by the relevant decision-making authorities.
Importantly, this analysis represents a snapshot of a pre-renegotiation phase. The subsequent alignment of acquisition prices between SC and IV formulations, observed both nationally and regionally, supports the interpretation that earlier cost differentials were not entirely justified by underlying productive factors. This price convergence reinforces the analytical conclusions of the model and highlights its utility as a decision-support tool to identify market asymmetries and inform evidence-based pricing and adoption strategies.
Consequently, implementation decisions should remain contingent on current local prices and patient demand. In high-volume centers with waiting lists or capacity constraints, SC adoption can unlock tangible efficiency gains and organizational value. Conversely, in settings without latent demand, a full switch to SC may remain economically unfavorable unless acquisition parity is achieved.
In summary, SC formulations should be regarded not merely as alternative administration routes but as potential enablers of organizational innovation and more sustainable models of care. The proposed framework can assist healthcare providers and policy makers in aligning therapeutic appropriateness with system sustainability, ensuring that innovation translates into improved access, efficiency, and equity across oncology services. Future applications could incorporate direct, indirect, and out-of-pocket patient costs to assess financial toxicity more comprehensively.
Supplementary material
The supplementary material for this article can be found at http://doi.org/10.1017/S0266462326104000.
Data availability statement
The data underlying the findings described in this manuscript are deposited in the Zenodo repository within the Veneto Institute of Oncology IOV IRCCS community, but they are not publicly available. The anonymized datasets are available from the corresponding author G.Z. (giorgia.zorzetto@iov.veneto.it) upon reasonable request.
Author contribution
Conceptualization/methodology/formal analysis/data curation/writing – original draft/visualization: Giorgia Zorzetto and Alberto Russi. Formal analysis/methodology/data curation: Alessandro Giuriola and Giuseppe Di Blasio. Investigation/methodology/writing – review and editing: Sara Lonardi, Valentina Guarneri, Marco Maruzzo, Maria Vittoria Dieci, Giulia Pasello, Michele Gottardi, Silvia Cognolato, Nicoletta Rigamonti, Chiara Mioni, Flavio Cazzador, Giulia Badaile, Francesca Pipitone, Daniela Grosso and Patrizia Simionato. Supervision/validation/project administration/writing – review and editing: Giovanna Scroccaro and Marina Coppola. All authors read and approved the final version of the manuscript.
Competing interests
The authors declare none.
